3SBio (STU:83B) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:83B 3SBio Inc STU:83B
89 GF Score
Price €1.85
GF Value €1.44
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is 3SBio FFO per Share?

FFO per Share only applies to REITs.

STU:83B
89GF Score
3SBio Inc STU:83B
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is 3SBio (STU:83B) Overvalued in 2026?

Based on GuruFocus' analysis, 3SBio stock appears to be overvalued. The current stock price of €1.85 is trading 28.5% above its estimated GF Value™ of €1.44. GuruFocus considers 3SBio to be Modestly Overvalued.

Key valuation signals for STU:83B:

  • FFO per Share:
  • GF Value™: €1.44 vs. price of €1.85 (28.5% above fair value)
  • GF Score™: 89/100 with 1 warning sign

No single metric tells the full story. See the STU:83B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

3SBio Business Description

Other Exchanges TRSBF:USA01530:Hong Kong
Address No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
89GF Score

Get the complete analysis for STU:83B

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.85
Price
€1.44
GF Value